secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2023-06-23T23:59:59+00:00
Accession:  0001193125-23-173796
Event type: other
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Therapeutics recasts FY2022 financials after reverse split; reports net loss of $37.7M
--------------------------------------------------------------------------------

- Annual meeting elected directors Heyman and Kintz; ratified Deloitte & Touche as auditor for FY2023.
- Recasted FY2022 net loss of $37.7M ($12.05 per share) vs $24.7M in FY2021.
- R&D expense rose 51% to $31.0M; G&A expense increased to $7.8M.
- Cash and equivalents totaled $75.5M at Dec 31, 2022, down from $110.0M a year earlier.
- Company expects current cash to fund operations for at least 12 months from March 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312523173796/0001193125-23-173796-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312523173796/d514661d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-173796

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer